Timothy M. Kuzel

Timothy M. Kuzel

Auto-generated profile, based on publicly available information

Timothy M. Kuzel

Rush University Medical Center, Chicago, IL

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 January 2023 in Cells
Verified
Journal Article
Open access
PDF file
SWStephen J. Wood
Stephen J. Wood
TKTimothy M. Kuzel
Timothy M. Kuzel
Sasha H ShafikhaniSasha H Shafikhani
Sasha H Shafikhani
Pseudomonas aeruginosa is an important Gram-negative opportunistic pathogen which causes many severe acute and chronic infections with high morbidity, and mortality rates as high as 40%. What makes P. aeruginosa a particularly challenging pathogen is its high intrinsic and acquired resistance to many of the available antibiotics. In this review, we review the important acute and chronic infections caused by this pathogen. We next discuss various animal models which have been developed to evaluate P. aeruginosa pathogenesis and assess therapeutics against this pathogen. Next, we review current treatments (antibiotics and vaccines) and provide an overview of their efficacies and their limitations. Finally, we highlight exciting literature on novel antibiotic-free strategies to control P. aeruginosa infections.

18 December 2018 in Journal of Clinical Investigation
Verified
Journal Article
Closed access
PDF file
BSBing Song
Bing Song
SPSu-Hong Park
Su-Hong Park
JZJonathan C. Zhao
Jonathan C. Zhao
KFKa-Wing Fong
Ka-Wing Fong
SLShangze Li
Shangze Li
JYJindan Yu
Jindan Yu
Prostate cancer (PCa) progressed to castration resistance (CRPC) is a fatal disease. CRPC tumors develop resistance to new-generation anti-androgen enzalutamide through lineage plasticity, characterized by epithelial-mesenchymal transition (EMT) and basal-like phenotype. FOXA1 is a transcription factor essential for epithelial lineage differentiation. Here, we demonstrate that FOXA1 loss leads to remarkable up-regulation of transforming growth factor beta 3 (TGFB3), which encodes a ligand of TGF-β pathway. Mechanistically, this is due to genomic occupancy of FOXA1 on an upstream enhancer of TGFB3 gene to directly inhibit its transcription. Functionally, FOXA1 down-regulation induces TGF-β signaling, EMT, and cell motility, which is effectively blocked by TGF-β receptor I inhibitor Galunisertib (LY2157299). Tissue microarray analysis confirmed reduced levels of FOXA1 protein and a concordant increase in TGF-β signaling, indicated by SMAD2 phosphorylation, in CRPC as compared to primary tumors. Importantly, combinatorial LY2157299 treatment sensitized PCa cells to enzalutamide, leading to synergistic effects in inhibiting cell invasion in vitro and xenograft CRPC tumor growth and metastasis in vivo. Therefore, our study establishes FOXA1 as an important regulator of lineage plasticity mediated in part by TGF-β signaling and supports a novel therapeutic strategy to control lineage switching and potentially extend clinical response to antiandrogen therapies.

1 December 2018 in The Journal of Immunology
Verified
Journal Article
Closed access
PDF file
ALAlan Long
Alan Long
DDDonye Dominguez
Donye Dominguez
LQLei Qin
Lei Qin
SCSiqi Chen
Siqi Chen
JFJie Fan
Jie Fan
BZBin Zhang
Bin Zhang
Although a number of studies have recently explored the contribution of the adaptive immunity in IL-33–mediated antitumor effects, innate immune involvement has been poorly characterized. Utilizing Rag1−/− mice (lacking T and B lymphocytes), we show in this study that either systemic administration of recombinant IL-33 or ectopic expression of IL-33 in melanoma cells is sufficient to inhibit tumor growth independent of adaptive antitumor immunity. We have demonstrated that IL-33–mediated antitumor effects depend on expansion and activation of NK cells. Interestingly, IL-33 also promoted the expansion of active type 2 innate lymphoid cells (ILC2s) via its receptor, ST2, which in turn inhibited NK activation and cytotoxicity. This IL-33–induced ILC2 activity coincided with greater expression of the immunosuppressive ectoenzyme CD73. Removal of CD73 from ILC2s in culture with NK cells resulted in markedly increased activation levels in NK cells, offering a potential mechanism by which ILC2s might suppress NK cell–mediated tumor killing. Thus, our data reveal an important contribution of IL-33–induced ILC2 to tumor growth by weakening NK cell activation and tumor killing, regardless of adaptive immunity.

Verified
Journal Article
Open access
PDF file
MGMiles Grunvald
Miles Grunvald
RJRichard Jacobson
Richard Jacobson
TKTimothy M. Kuzel
Timothy M. Kuzel
SPSam Pappas
Sam Pappas
AMAshiq Masood
Ashiq Masood
Pancreatic cancer is a challenging disease with a low 5-year survival rate. There are areas for improvement in the tools used for screening, diagnosis, prognosis, treatment selection, and assessing treatment response. Liquid biopsy, particularly cell free DNA liquid biopsy, has shown promise as an adjunct to our standard care for pancreatic cancer patients, but has not yet been universally adopted into regular use by clinicians. In this publication, we aim to review cfDNA liquid biopsy in pancreatic cancer with an emphasis on current techniques, clinical utility, and areas of active investigation. We feel that researchers and clinicians alike should be familiar with this exciting modality as it gains increasing importance in the care of cancer patients.

10 September 2021 in Journal of Investigative Dermatology
Verified
Journal Article
Closed access
RRRuchi Roy
Ruchi Roy
JZJanet Patricia Zayas
Janet Patricia Zayas
MMMohamed F. Mohamed
Mohamed F. Mohamed
AAAnahita Aboonabi
Anahita Aboonabi
KDKaylee Delgado
Kaylee Delgado
Sasha H ShafikhaniSasha H Shafikhani
Sasha H Shafikhani

8 August 2024 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
MHMaha Hussain
Maha Hussain
MKMasha Kocherginsky
Masha Kocherginsky
NANeeraj Agarwal
Neeraj Agarwal
NANabil Adra
Nabil Adra
JZJingsong Zhang
Jingsong Zhang
Emmanuel S. AntonarakisEmmanuel S. Antonarakis
Emmanuel S. Antonarakis
Purpose: Deleterious germline/somatic homologous recombination repair mutations (HRRm) are present in ∼25% of patients with metastatic castration-resistant prostate cancer (mCRPC). Preclinically, poly(ADP-ribose) polymerase (PARP) inhibition demonstrated synergism with androgen receptor pathway (ARP)–targeted therapy. This trial evaluated the efficacy of ARP inhibitor versus PARP inhibitor versus their combination as first-line therapy in patients with mCRPC with HRRms. Patients and Methods: BRCAAway is a biomarker preselected, randomized, phase 2 trial. Patients with BRCA1/2 and/or ATM alterations were randomized 1:1:1 to Arm1: abiraterone (1,000 mg)/prednisone (5 mg BID) (Abi/pred), Arm2: olaparib (300 mg BID) (Ola), or Arm3: abiraterone/prednisone + olaparib (Abi/pred + Ola). Single-agent arms could cross over at progression. Exploratory Arm4 patients with other HRRms received olaparib alone. The primary endpoint was progression-free survival (PFS), and secondary endpoints were objective response, PSA response, and safety. Results: Sixty-one of 165 eligible patients had BRCA1/2 or ATM mutations: median age: 67 (IQR, 62–73) years. Mutations: BRCA1 n = 3, BRCA2 n = 46, ATM n = 11, and multiple n = 1; 33 germline and 28 somatic mutations. Median PFS [95% confidence interval (CI)]: Abi/pred, 8.6 months (m; 2.9, 17), Ola, 14 m (8.4, 20), and Abi/pred + Ola, 39 m [22, not reached (NR)]. There were no G4/5 adverse events; 8/19 patients on Abi/pred treatment crossed over to Ola, and 8/21 vice versa. Median PFS (95% CI) from crossover: Ola-after-Abi/pred, 8.3 m (5.5, 15) and Abi/pred-after-Ola, 7.2 m (2.8, NR). Median PFS (95% CI) from randomization: Ola-after-Abi/pred, 16 m (7.8, 25) and Abi/pred-after-Ola, 16 m (11, NR). Seventeen of 165 patients with other HRRms received olaparib: median PFS (95% CI): 5.5 m (2, 11). Conclusions: In patients with mCRPC with BRCA1/2 or ATM HRRm, Abi/pred + Ola was well tolerated and demonstrated longer PFS versus either agent alone or sequentially.